72.00
+2.35
(3.37%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 69.65 - 72.42 |
| 52 week | 37.77 - 77.11 |
| Open | 70.13 |
| Vol / Avg. | 1.57M/1.62M |
| Mkt cap | 8.95B |
| P/E | 96.26 |
| Div/yield | - |
| EPS | 0.75 |
| Shares | 124.28M |
| Beta | 0.64 |
| Inst. own | 116% |
Events
Jul 22, 2013
Q2 2013 Illumina, Inc. Earnings Release
May 29, 2013
Illumina, Inc. Annual Shareholder Meeting
- 1:00PM EDT -
May 20, 2013
Illumina, Inc. at UBS Global Healthcare Conference
- 11:30AM EDT -
May 14, 2013
Illumina, Inc. at Bank of America Merrill Lynch Health Care Conference -
May 8, 2013
Illumina, Inc. at Robert W Baird and Co Growth Stock Conference -
Apr 22, 2013
Q1 2013 Illumina, Inc. Earnings Conference Call -
Mar 6, 2013
Illumina, Inc. at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -6.82% | 13.17% |
| Operating margin | -13.64% | 17.48% |
| EBITD margin | - | 27.77% |
| Return on average assets | -3.41% | 6.35% |
| Return on average equity | -6.89% | 12.64% |
| Employees | 2,400 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations. In September 2012, it acquired BlueGnome Ltd. In February 2013, it completed the acquisition of Verinata Health, Inc.
Officers and directors
| William H. Rastetter Ph.D. | Chairman of the Board | |
| Jay T. Flatley | President, Chief Executive Officer, Director | |
| Marc A. Stapley | Chief Financial Officer, Senior Vice President | |
| David R. Walt Ph.D. | Chairman - Scientific Advisory Board, Independent Director | |
| Mostafa Ronaghi Ph.D. | Chief Technology Officer, Senior Vice President | |
| Charles Dadswell | Senior Vice President, General Counsel, Secretary | |
| Gregory F. Heath Ph.D. | Senior Vice President, General Manager - Diagnostics | |
| Christian O. Henry | Senior Vice President, General Manager - Genetic Analysis | |
| Mark L. Lewis | Senior Vice President, General Manager - Molecular Biology and PCR | |
| Matthew L. Posard | Senior Vice President, General Manager - Translational and Consumer Genomics |